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Abstract  21 
Background 22 
Non-alcoholic fatty liver disease (NAFLD) is a serious health problem affecting ~25% of the 23 
global population. While NAFLD pathogenesis is still unclear, multiple NAFLD parameters, 24 
including reduced insulin sensitivity, impaired glucose metabolism and increased oxidative 25 
stress are hypothesised to foster the formation of advance glycation end-products (AGEs). 26 
Given the link of AGEs with end organ damage, there is scope to examine the role of the 27 
AGE/RAGE axis activation in liver injury and NAFLD. 28 
Methods 29 
Age, sex and body mass index matched normo-glycemic NAFLD adults (n=58) and healthy 30 
controls (n=58) were enrolled in the study. AGEs were analysed by liquid chromatography-mass 31 
spectrometry (CML, CEL), fluorescence (pentosidine, AGE fluorescence), colorimetry 32 
(fructosamine) and ELISA (sRAGE). Their association with liver function, inflammation, fibrosis 33 
and stage of NAFLD was examined. 34 
Results 35 
Early and advanced glycation end-products, except Nε-carboxymethyl-L-lysine (CML), were 10-36 
30% higher, sRAGE levels 1.7-fold lower, and glycation/sRAGE ratios 4-fold higher in the NAFLD 37 
cases compared to controls. While AGEs presented weak to moderate correlations with indices 38 
of liver function and damage (AST/ALT, HOMA-IR, TNF-α and TGF-β1), including sRAGE to 39 
characterize the AGEs/sRAGE axis strengthened the associations observed. High 40 
glycation/sRAGE ratios were associated with 1.3 to 14-fold likelihood of lower AST/ALT ratios. 41 
The sum of AGEs/sRAGE ratios accurately distinguished between healthy controls and NAFLD 42 
patients (area under the curve of 0.85). Elevated AGEs/sRAGE (>7.8mmol/pmol) was associated 43 
with a 12-fold likelihood of the presence of NAFLD. 44 
Conclusion 45 
These findings strengthen the involvement of AGEs-RAGE axis in liver injury and the 46 
pathogenesis of NAFLD. 47 
Keywords 48 
NAFLD, glycation, biomarker, liver, sRAGE, CML 49 
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1.1 Introduction 50 
Non-alcoholic fatty liver disease (NAFLD) results from fat accumulation in the liver (fat>5% of 51 
liver weight), for reasons other than excess alcohol consumption [1]. NAFLD, the most common 52 
cause of chronic liver disease in Western countries, covers a spectrum of liver damage from 53 
simple fatty liver to non-alcoholic steatohepatitis [2] and cirrhosis [3]. Affecting ~25% of the 54 
general population, NAFLD is expected to become the next global epidemic as its pathogenesis 55 
is closely linked to obesity and metabolic syndrome [4, 5]. 56 
Insulin resistance (IR) is a prevailing factor in the complex and still-unclear disease 57 
pathogenesis [6]. Lipid accumulation in the liver, followed by increased oxidative stress and 58 
cytokine levels is proposed to lead to necro-inflammation, fibrosis and cirrhosis (two-hit 59 
model). Alternatively, multiple insults, such as insulin resistance, free fatty acid (FFA) flux, 60 
oxidative and cytokine-induced stress, adipocytokine imbalance and bacteria toxins could act in 61 
parallel to induce progressive damage leading to steatosis (multiple-hit model) [7, 8]. 62 
Reduced insulin sensitivity and impaired glucose and lipid metabolism [9] favour 63 
advance glycation end-products (AGEs) formation, contributing to liver damage [10]. AGEs are 64 
formed by the non-enzymatic reaction of a reducing sugar or oxidized lipid with an amino acid, 65 
resulting in alteration in the structure and function of proteins [11]. Nε-carboxyethyl-L-lysine 66 
(CEL), Nε-carboxymethyl-L-lysine (CML), and pentosidine are the most common and best 67 
characterized AGEs used as biomarkers of disease progression [12, 13]. AGEs exert their effect 68 
by binding to the AGEs receptors (RAGE) [11]. The AGE/RAGE interaction induces the activation 69 
of several intracellular pathways and further synthesis of cytokines [13, 14]. Upregulation of 70 
these biological processes lead to further inflammation, reactive oxygen species (ROS) and IR, 71 
promoting further AGEs production and in the case of liver fibrosis [15, 16]. While in circulation, 72 
AGEs may also bind with the soluble variants of the receptor (sRAGE and esRAGE) which act as 73 
scavengers leading to AGEs elimination and prevention of the AGE/RAGE axis activation [11]. 74 
In vitro and in vivo studies have strengthened the hypothesis that high AGEs levels 75 
(endogenous formation and exogenous intake from meat, fat and highly processed food [17, 76 
18]) and AGEs/RAGE axis activation lead to oxidative stress and hepatic inflammation [10]. 77 
Lower levels of sRAGE levels are also present in hyperglycemic [19] and hypertensive [20] 78 
subjects with IR and components of the metabolic syndrome [21] compared to non-diabetic 79 
normotensive subjects. On the contrary, Type1/2 Diabetes Mellitus subjects with renal disease 80 
have higher sRAGE levels compare to healthy controls [22]. AGEs and/or sRAGE levels (in 81 
isolation) and AGEs/sRAGE ratios have been proposed as potential novel biomarkers for end 82 
5 
 
organ damage [22-24], but the relationship between sRAGE levels and glycaemic control / 83 
insulin resistance remains unclear [25]. 84 
To-date, there is a lack of human studies investigating the role of AGEs and (e)sRAGE in 85 
the pathogenesis of NAFLD. The aim of the present study was to simultaneously examine, for 86 
the first time, early (fructosamine) and advanced glycation products (CML, CEL and 87 
pentosidine), as well as sRAGE levels and their respective ratios as proxies for liver 88 
injury/damage in a NAFLD case-control study of normo-glycemic adults. 89 
1.2 Material and methods 90 
1.2.1 Study population 91 
Briefly, 58 adults with recent NAFLD diagnosis (based on elevated liver enzymes levels, 92 
ultrasound hepatic steatosis evidence and exclusion of any other liver injury) and 58 healthy 93 
adults matched for age, sex and BMI with the aforementioned cases were recruited [26, 27]. 94 
Patients were excluded if following a weight-loss diet, had changed dietary habits after 95 
diagnosis, had type 1 or 2 diabetes mellitus or any malignancy. The study was approved by the 96 
Ethics Committees of the Hippokration General Hospital of Athens and Harokopio University 97 
and was executed in accordance with the Declaration of Helsinki. Written informed consent 98 
was obtained from each participant. 99 
Medical records and anthropometric measurements, along with other variables 100 
previously described [26-28], were recorded for each participant. Liver stiffness measurements 101 
(LSM) by transient elastography (FibroScan®, Echosens, France) were available in 45 of the 58 102 
NAFLD patients, and liver biopsies were available for 22 of the NAFLD subjects. Patients were 103 
classified as having simple liver steatosis or NASH, based on the liver injury pattern and the 104 
criteria of Brunt et al.[29], modified by Kleiner et al [30]. 105 
1.2.2 Biochemical markers 106 
12-h fasting blood was collected from all subjects. Glucose was measured colorimetrically 107 
(Cobas 8000, Roche), insulin by chemiluminescence (Centaur analyzer, Siemens) and HOMA-IR 108 
(Homeostasis Model of Assessment-Insulin Resistance) was calculated [31]. Inflammatory 109 
biomarkers (TNF-α, Il-6, IL-8, adiponectin) were measured by enzyme-linked immunosorbent 110 
assay (ELISA, R&D Systems, Minneapolis, MN, USA) and High sensitive CRP (hsCRP) using a 111 
nephelometric assay (BN II® nephelometer, Siemens). Markers of apoptosis, fas ligand and 112 
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caspase-cleaved cytokeratin 18 fragment (m30) were included as non-invasive biomarkers for 113 
NAFLD diagnosis. Liver enzymes; aspartate aminotransferase (AST), alanine aminotransferase 114 
(ALT) and γ-glutamyl transpeptidase (γGT), were obtained from patients’ medical records or 115 
analyzed using routine commercial assays [32].  116 
1.2.3 Chemicals and reagents 117 
CML, CEL, pentosidine and CML-d2 (HPLC-grade) were from PolyPeptide Laboratories France. 118 
Nanofluoropentanoic acid (NFPA), nitroblue tetrazolium, 1-deoxy-1-morpholinofructose (DMF), 119 
sodium borohydride, sodium tetraborate, boric acid, sodium carbonate, trichloroacetic acid, 120 
hydrochloric acid and PBS were purchased from Sigma Aldrich. Acetonitrile and water were 121 
HPLC-grade from VWR International. 122 
1.2.4 Glycation biomarkers 123 
1.2.4.1 Fructosamine (NBT Assay) 124 
Fructosamine was analyzed using the modified NBT assay by Vlassopoulos et al. [33]. Serum 125 
(12µL, duplicates) was added to sodium carbonate buffer (120µL, 0.375M) and nitroblue 126 
tetrazolium (120μL, 1.2mM). After incubation (10 and 15min, 37oC), absorbencies were 127 
measured at 550nm (Multiskan Spectrum v1.2, Thermo Scientific). DMF was used as a standard 128 
(0–2mM). The method presented a limit of quantification of 0.04mM, with 2.45 and 0.74% 129 
coefficient of variation (CV) for repeatability and reproducibility.  130 
1.2.4.2 AGE fluorescence  131 
Serum (25µL, duplicates) was diluted in PBS (100μL) and measured fluorometrically 132 
(λemission=370 nm, λexcitation=440nm, SpectraMax M2e, SoftMax®Pro software). The repeatability 133 
and reproducibility of the method were CV 3.7% and CV 1.2%, respectively. 134 
1.2.4.3 sRAGE 135 
sRAGE levels were determined using a commercial ELISA kit (RayBio® Human RAGE, Tebu-bio, 136 
UK) specific for human RAGE (MOK protein kinase, Gene ID: 5891). Duplicate samples (diluted 137 
1:5 in PBS) and RAGE standards (0–1.5ng/mL) absorbencies were read at 450nm (Multiskan 138 
Spectrum v1.2, Thermo Scientific). The limit of detection of the kit was 3pg/mL (2SD of the 139 
blank). Repeatability and reproducibility presented a CV<10%. 140 
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1.2.4.4 AGEs quantification by HPLC-fluorescence-MS 141 
1.2.4.4.1 Serum treatment  142 
Serum was prepared as previously described [34]: 600μL of 100mM sodium borohydride 143 
dissolved in 200mM borate buffer (pH 9.2) was added to the serum (25μL, 1:5 in water). 144 
Proteins were precipitated with trichloroacetic acid (2mL, 200mg/mL). After centrifugation 145 
(10min, 2000g), the protein pellet was washed with trichloroacetic acid (1mL, 100mg/mL) and 146 
re-centrifuged (10min, 2000g). Hydrochloric acid (400µL, 6M) was added to the pellet, followed 147 
by hydrolysis (20h, 110°C), before evaporation to dryness (80°C, under nitrogen). The residue 148 
was resuspended in NFPA (500µL, 5mM), and filtered (4mm, 0.22μm PVDF) before HPLC-149 
fluorescence-MS analysis. 150 
1.2.4.4.2 Quality assessment 151 
Spiked serum controls were 0.1μmol/L (low), 1.0μmol/L (medium), and 10μmol/L (high) and 152 
CML, CEL and pentosidine standards ranged from 0.01-2.0μmol/L in 5mmol/L NFPA in water. All 153 
analysis included a glassware control and reactive control samples. Samples were spiked with 154 
the internal standard (CML-d2, final concentration 1.0μmol/L). The method was assessed for 155 
linearity (0–2mmol/L, r ≥.99) and recovery (0.1, 1 and 10μmol/L). The LOQs (signal-to-noise of 156 
10) of CML, CEL and pentosidine were 0.01, 0.015 and 0.005 µmol/L, respectively. Recoveries 157 
were 79–115% and relative errors were below 15%. Inter- and intra-variation were below 13%.  158 
1.2.4.4.3 CML & CEL 159 
Analysis was carried out on a Thermo Scientific ExactiveTM Plus Orbitrap LCMS Mass 160 
Spectrometer, with photodiode array UV –detector coupled to an OrbitrapTM MS analyser; 161 
using the Thermo Xcalibur software version Exactive Plus Tune 2.1 (Thermo Scientific Inc, 162 
Waltham, MA USA). 163 
Glycated products (10μL) were separated using a Hypersil GOLD C18 reversed phase 164 
(1.9μm) column (2.1mm id X 100mm column) at 30°C. The mobile phase included H2O (eluent 165 
A) and acetonitrile (eluent B); both with 5mmol/L NFPA, at the following gradient: 0–7min: 10–166 
18% B, 7–9min: 18–50% B, 9–12min: 50–80 % B, 12–13min: 80–100% B, 13–15min: 100% B 167 
(0.3mL/min), 15–17min: 100–10% B, and 3min of equilibrium with a flow rate of 0.2mL/min. 168 
Mass spectrometry detection was performed using an electron spray ionization interface in the 169 
positive ion mode. The ions were analyzed using a scan from 160 to 384m/z (1000msec) with a 170 
capillary voltage of 42.5V at 380°C. 171 
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1.2.4.4.4 Pentosidine 172 
Pentosidine analysis was carried out on a Thermo Finnigan Surveyor, photodiode array (PDA) 173 
detector, coupled to a spectrofluorometer (Jasco FP-920, Jasco Benelux, Maarssen, The 174 
Netherlands); using the Thermo Xcalibur software version 1.4 SR1 (Thermo Scientific Inc, 175 
Waltham, MA USA). Pentosidine (80μL) was separated on a Synergi MAX-RP 80 Å column (250 x 176 
4.6mm, 4μm) at 30°C. The mobile phase included H2O (solvent A) and acetonitrile (solvent B); 177 
both with 5mmol/L NFPA, at the following gradient: 0–8min: 10–20% B, 8–10min: 20–60% B, 178 
10–13min: 60–94% B, 13–14min: 94–100% B, 14–20min: 100% B (flow rate: 1400mL/min), 20–179 
23min: 100–10% B, and 5min of equilibrium, flow rate of 1mL/min. Fluorometric detection was 180 
set at excitation and emission wavelength of 335 and 385nm, respectively. 181 
1.2.4.4.5 AGEs/sRAGE ratio 182 
AGEs levels were divided by sRAGE levels to create a ratio (mmol of AGEs per pmol of sRAGE) 183 
that considers AGEs/RAGE interaction in disease previously suggested by others [22-24]. 184 
1.2.5 Statistical analysis  185 
Data are presented as mean (SD) for continuous variables, and as frequencies for categorical 186 
variables. Data normality was evaluated using the Shapiro-Wilk test. Differences between cases 187 
and controls (including levels of AGEs and sRAGE among the stage of the disease; simple liver 188 
steatosis and NASH) were determined by Student’s t-test (parametric), Mann-Whitney U Test 189 
(non-parametric) or chi-squared test (categorical variables). Spearman’s or Pearson’s 190 
correlation coefficients were used to assessing the univariate correlations of AGEs with liver 191 
function and inflammation biomarkers. Multinominal logistic regression analysis was used to 192 
evaluate the independent contribution of the glycation products/sRAGE axis (as untransformed 193 
continuous variable) with liver injury described as AST/ALT (categorical variable). The AST/ALT 194 
levels were divided into quartiles (with the highest quartile, >1.72, as the reference group). The 195 
independent associations of glycation products/sRAGE with AST/ALT were examined without 196 
adjustment (model 1), adjusted for age, abdominal fat level and gender (models 2-3), IL-6 and 197 
hsCRP (model 3). 198 
To assess the usefulness of glycation biomarkers in differentiating between healthy 199 
controls and NAFLD cases, cut-off values, sensitivity and specificity for each parameter were 200 
calculated followed by the construction of receiver operating characteristic (ROC) curve 201 
(plotting the sensitivity and reverse specificity at each value) [35]. Binomial logistic regression 202 
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analysis was performed to estimate the association between glycation biomarkers (binary 203 
variable, according to the cut-off values) and presence of NAFLD (binary variable) adjusted by 204 
age, sex, abdominal fat level (modes 1), AST/ALT, γGT, HOMA-IR (model 2), IL-6 and TNF- α 205 
(model 3). Additionally, binomial logistic regression analysis was performed to estimate the 206 
association of glycation biomarkers (as untransformed continuous variable) with the presence 207 
of NASH (vs simple steatosis, binary variable) and fibrosis (defined as LSM>6.6kPa cut-off, 208 
binary variable) unadjusted (model 1) and adjusted by age and AST/ALT, (model 2). Reported p-209 
values were based on two-sided tests, α=0.05. The SPSS software (IBM® SPSS® Statistics Version 210 
22, 2013, U.S.A) was used. 211 
1.3 Results  212 
1.3.1 General characteristics of the subjects 213 
Subjects were aged 45±12 years, with a BMI of 28.2±3.8kg/m2, a waist circumference of 214 
98±9.0cm (Table 1). Approximately half (46%) of subjects had increased waist circumference 215 
(women >88 cm and men >102 cm). 216 
Table 1. General characteristics of the 58 cases with non-alcoholic fatty liver disease (NAFLD) and 217 
their matched healthy controls. 218 
 Cases (n=58) Controls (n=58) p value 
Gender – female, n (%) 22 (37.9) 22 (37.9) 0.99 
Age (years) 45 (12) 45 (12) 0.96 
BMI (kg/m2) 28.7 (4.0) 27.7 (3.6) 0.14 
Female  30.8 (5.0) 29.1 (4.6) 0.25 
Male 27.5 (2.5) 26.8 (2.5) 0.26 
Waist circumference (cm)    
Female  101.0 (10.5) 95.3 (11.0) 0.09 
Male 99.1 (7.2) 96.6 (8.0) 0.18 
Abdominal fat level (%) 15.0 (4.4) 12.5 (5.1) 0.008 
Insulin (IU/mL)  12.5 (8.5 – 16.0) 7.0 (5.0 – 10.0) <0.001 
Glucose (mmol/L) 5.0 (0.7) 4.8 (0.6) 0.07 
HOMA-IR a 3.1 (2.2) 1.9 (1.5) <0.001 
Data are presented as means (SD), frequencies or median (interquartile range). Differences between cases 
and their matched controls were observed using X2 test, 2-samples t test or Mann-Whitney U Test. 
Abdominal fat levels were assessed by abdominal bioelectrical impedance analysis. BMI, body mass index; 
HOMA-IR, Homeostasis Model of Assessment of insulin resistance 
 219 
1.3.2 Glycation biomarkers  220 
Early (fructosamine) and advanced glycation markers (CEL, pentosidine and AGE fluorescence) 221 
levels were higher in cases compared to controls (Table 2). A notable exception was CML which 222 
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remained similar between groups. Meanwhile, sRAGE serum levels were 1.7-fold lower in cases 223 
compared to controls. These differences were maintained when comparing those cases with 224 
available biopsy (n=22) and matched healthy controls (n= 22, Supplement 2). From a 225 
pathophysiological perspective, there is scope to study the amount of ‘free’ CML and CEL that 226 
could interact with RAGE and activate the AGE/RAGE axis. Moreover, calculating the relative 227 
concentration of AGEs to their scavenger sRAGE has been proposed as a proxy of ‘free’ AGEs. In 228 
this study, the CML/sRAGE, CEL/sRAGE and AGEs/sRAGE ratios were four times higher in cases 229 
compared to controls (Table 2). Among the 22 NAFLD cases with available biopsies, the serum 230 
levels of glycation did not differ according to the grade of necro-inflammation and stage of 231 
fibrosis (Brunt [29], Supplement 3 and Supplement 4, respectively), as well as the severity of 232 
steatosis according to Kleiner [30] (Supplement 5). 233 
Table 2. Glycation biomarkers levels in the 58 patients with non-alcoholic fatty liver disease 234 
(NAFLD) and their matched healthy controls. 235 
 Cases (n=58) Controls (n=58) p-value 
Fructosamine (mM DMF) 1.1 (0.2) 0.9 (0.2) <0.001  
AGE fluo (AU)a 501.4 (411.6 – 595.4) 412.2 (375.2 – 443.2) <0.001  
AGEs (mmol/mol) 135.2 (34.7) 105.3 (29.5) <0.001  
CML (mmol/mol) 10.6 (3.8) 9.9 (2.5) 0.26  
CEL (mmol/mol) 122.9 (34.7) 93.9 (30.7) <0.001  
Pentosidine (mmol/mol)a 1.6 (1.5 – 1.9) 1.5 (1.4 – 1.7) 0.02  
sRAGE (pg/L)a 363.0 (252.3 – 513.1) 630.7 (509.8 – 513.1 <0.001  
CML/sRAGE (mmol/pmol) 2.5 (5.4) 0.6 (0.3) 0.01  
CEL/sRAGE (mmol/pmol) 22.1 (29.2) 5.5 (2.8) <0.001  
AGEs/sRAGE (mmol/pmol) 25.0 (34.3) 6.2 (3.0) <0.001  
Data are presented as means (SD) or a median (interquartile range). Differences between cases and 
their matched controls (match by age, sex and BMI) were observed using 2-samples t test or Mann-
Whitney U Test. AGEs: advance glycation end products, CEL: Nε-carboxyethyl-L-lysine, CML: Nε-
carboxymethyl-L-lysine, sRAGE: AGEs soluble receptor. 
 236 
1.3.3 Glycation, hepatic function, inflammation and damage 237 
To explore the role of the AGE-RAGE axis in liver injury, glycation products and their 238 
associations with selected liver function, liver damage and inflammation biomarkers in the 239 
whole sample of cases and controls (N=116) are presented in Table 3 (and Supplementary 240 
Figures 1-9). The association between glycation products and biomarkers among cases only and 241 
controls only are presented in Supplements 6 and 7, respectively. Biochemical markers have 242 
been previously described [36] and are shown in Supplement 1. No associations were detected 243 
between CML and any of the markers studied. Serum levels of all glycation markers, except 244 
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CML and AGE fluorescence, were weakly to moderately associated with HOMA-IR; the same 245 
was true for AGEs/sRAGE ratios (Table 3). 246 
All glycation markers, but CML, were weakly to moderately positively associated with 247 
the transaminase ALT, but not the transaminase AST (weak association with fructosamine and 248 
AGE fluorescence) or the transpeptidase γGT (weak association with the sum of the three AGE 249 
markers). Stronger negative associations were seen for sRAGE and the AGE/RAGE ratios. Using 250 
the AST/ALT liver damage ratio, associations were maintained for all glycation biomarkers 251 
(except CML) and all AGEs/sRAGE ratios. However, neither glycation markers, nor sRAGE nor 252 
AGE/RAGE ratios did correlate with the non-invasive markers of apoptosis for NASH, fas and 253 
m30 (data not shown). Only fructosamine and AGE fluorescence did correlate with liver 254 
stiffness (r=-0.32, p=0.04 and r=-0.39, p=0.01, respectively). Early and advanced glycation 255 
products were weakly associated to the growth factor TGF-β1 (Table 3) but not with VEGF (data 256 
not presented).  257 
Table 3. Spearman (rho) correlations between glycated products and sRAGE, and liver function 258 
and inflammation biomarkers in the 116 subjects. 259 
 ALT AST AST/ALT γGT HOMA-
IR 
TGF-
β1 
TNF-α IL-6 hsCRP 
AGEs (sum of) 0.28** 0.16 -0.28** 0.21* 0.26** 0.26** 0.05 0.00 0.06 
CML 0.10 0.08 -0.06 0.10 -0.02 0.00 0.05 0.04 -0.15 
CEL 0.25** 0.14 -0.20* 0.18 0.26** 0.25** 0.04 -0.07 0.06 
Pentosidine 0.20* 0.15 -0.20* 0.12 0.21* 0.05 0.17 -0.13 0.03 
Fructosamine 0.33** 0.23* -0.30** 0.17 0.21* 0.22* 0.02* -0.21* -0.12 
AGE 
fluorescence 
0.38** 0.20* -0.32** 0.35** 0.18 0.23* 0.37** -0.07 0.09 
sRAGE -0.40** -0.16 0.39** -0.44** -0.28** -0.16 -0.29** 0.01 -0.24* 
CML/sRAGE 0.40** 0.19 -0.41** 0.44** 0.20* 0.18 0.27** 0.04 0.17 
CEL/sRAGE 0.42** 0.18 -0.45** 0.43** 0.33** 0.26** 0.25** 0.02 0.21* 
AGEs/sRAGE 0.43** 0.18 -0.47** 0.44** 0.33** 0.27** 0.25** 0.04 0.21* 
*p < 0.05, ** p < 0.01; AGEs,advance glycation end products; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CEL, Nε-carboxyethyl-L-lysine; CML, Nε-carboxymethyl-L-lysine; γGT, γ-glutamyl 
transpeptidase; HOMA-IR, (log) Homeostasis Model of Assessment of insulin resistance; hsCRP, high-
sensitivity C-reactive protein; IL-6: interleukin 6; sRAGE, AGEs soluble receptor; TGF-β1, Transforming growth 
factor beta 1; TNF-α, Tumor necrosis factor-α. 
 260 
Associations with inflammatory markers TNF-α, IL6 and hs-CRP were inexistent for glycation 261 
products (and weak for fructosamine and AGE fluorescence). Only weak positive associations 262 
were observed between sRAGE and TNF-α and hs-CRP (but not IL-6). Calculating glycation 263 
products/sRAGE ratios (except CML/sRAGE) also revealed weak positive associations with TNF-264 
α but not hs-CRP (Table 3). No associations were observed for IL-8 or adiponectin levels (data 265 
not shown). While lower sRAGE levels alone were not associated with higher level of liver injury 266 
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(TGF-β1 and IL-6), the relative ratio of glycation products to sRAGE were. When the 267 
aforementioned correlations were carried-out for the cases and controls, separately, only 268 
correlations between fructosamine and IL-6 (r=-0.41, p=0.002) and AGEs/sRAGE and TNF-α 269 
(r=0.28, p=0.048) persisted in cases (Supplement 6). Among controls only (Supplement 7), AGEs 270 
correlated with ALT (r=-0.45, p=0.001), AST (r=-0.43, p=0.001), TNF-α (r=-0.38, p=0.005) and 271 
TGF-β1 levels (r=0.36, p=0.007). 272 
Glycation products/sRAGE were evaluated to predict liver injury using the simple 273 
predictive model AST/ALT ratio. Having higher levels of any of the AGEs/sRAGE, CEL/sRAGE and 274 
AGE fluorescence/sRAGE ratios increased the likelihood of having liver injury (low AST/ALT 275 
ratios). For every unit increase, there was a 27-33% increased likelihood of being in the lower 276 
quartiles of AST/ALT (higher liver injury) (OR from 1.27, CI 1.1–1.47 to 1.33, CI 1.15–1.55). 277 
Surprisingly, this relationship was much stronger for every unit increase of CML/sRAGE, with a 278 
14-fold increase in the likelihood of having liver injury (low AST/ALT) (OR from 13.28, CI 2.35–279 
75.2 to 14.27, CI 2.52–80.77). These associations were maintained/strengthened, especially for 280 
the CML/RAGE ratio after adjustment for age, abdominal fat, gender, IL-6 and hs-CRP (models 2 281 
& 3, Supplement 8). 282 
1.3.4 Association of glycation products and likelihood of presenting NAFLD 283 
NAFLD diagnosis and its stages (NASH and simple steatosis) was used as a clinical manifestation 284 
of liver injury. Glycation markers were assessed for their capacity to discriminate between 285 
controls and cases using ROC curves (Figure 1). CML, CEL, pentosidine and sRAGE presented a 286 
poor to fair ability to discriminate with an area under the ROC curve (AUC) below 0.78. The use 287 
of AGE-RAGE ratios (except CML/sRAGE), however, was better able to distinguish between case 288 
and controls: CEL/sRAGE and AGEs/sRAGE with an AUC of 0.85, and AGE fluorescence/sRAGE 289 
with an AUC of 0.83 - considered to present a “good” ability. 290 
 291 
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 292 
Figure 1. Receiver operating characteristic (ROC) curve for CEL/sRAGE (AUC= 0.844), 293 
AGEs/sRAGE (AUC= 0.845), sRAGE (AUC= 0.783), AGE fluorescence/sRAGE (AUC= 0.832) and 294 
CML/sRAGE (AUC= 0.779) to discriminate between NALFD patients and healthy controls. 295 
 296 
Cut-off values were selected at levels where glycation products yield sensitivities higher than 297 
75% while the corresponding specificities were maintained above 70%. Using a cut-off level of 298 
>7.8mmol/pmol for AGEs/sRAGE levels, a sensitivity and specificity of 81% and 77% were 299 
yielded. The same accuracy was observed for CEL/sRAGE with a cut-off level of >6.9mmol/pmol. 300 
The cut-off for sRAGE was set as <524pg/mL, to provide a sensitivity and specificity of 78% and 301 
71%, respectively. Using a cut-off of >87.4 AU/ng for AGE fluorescence/sRAGE achieved a 302 
sensitivity of 80% and a specificity of 79%. Using the cut-off values presented above, the odds 303 
ratio (OR) of having NAFLD was calculated adjusting for age, gender, abdominal fat mass, 304 
HOMA-IR, AST, γGT, TNF-α and IL-6 (Table 4). Increased likelihood of having NAFLD were seen 305 
for sRAGE levels below the cut-off (~1.6-fold), AGEs/sRAGE (11-fold), CEL/sRAGE (~10-fold), and 306 
AGE fluorescence/sRAGE (11-fold) above the cut-off. However, the likelihood of having NAFLD 307 
was not mantained for sRAGE and AGE fluorescence/sRAGE after adjusting for hepatic function 308 
and inflammatory biomarkers. 309 
310 
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 311 
Table 4. Logistic regression analysis models, exploring the association between cut-offs of 312 
glycated products/sRAGE ratio, sRAGE, and the likelihood of the presence of NAFLD (N= 58 cases 313 
and 58 controls). 314 
 Model 1a Model 2b Model 3c 
 OR 95% CI P OR 95% CI P OR 95% CI P 
sRAGE 
<524 pg/mL 
1.57 1.04-2.62 <0.001 1.05 052-2.62 0.25 0.52 0.05-2.10 0.33 
AGEs/sRAGE 
>7.8 mmol/pmol 
11.00 9.27-13 0.03 4.67 3.34-6.37 0.03 4.94 3.40-7.18 0.04 
CEL/sRAGE 
>6.9 mmol/pmol 
9.98 8.3-12 <0.001 4.32 3.07-6.07 0.03 4.65 3.05-7.07 0.04 
AGE 
fluorescence/sRAGE 
(>87.4 AU/ng) 
11.31 10-12.8 <0.001 10.37 0.16-12.53 0.08 10.23 0.17-12.21 0.08 
a Model 1: adjusted for age, sex and abdominal fat level. 
b Model 2: adjusted for age, sex, abdominal fat level, AST/ALT, HOMA-IR and γGT. 
c Model 3: adjusted for age, sex, abdominal fat level, AST/ALT, HOMA-IR, γGT, IL-6 and TNF- α levels. 
ALT: AST: aspartate aminotransferase, NAFLD: non-alcoholic fatty liver disease, OR: Odds Ratio, CI: Confidence 
Interval, CEL: Nε-carboxyethyl-L-lysine, AGEs: Nε-carboxymethyl-L-lysine, CEL and pentosidine advance glycation 
end products, sRAGE: AGEs soluble receptor, HOMA-IR: Homeostasis Model of Assessment of insulin resistance, 
IL-6: interleukin 6, γGT: γ-glutamyl transpeptidase, TNF-α: Tumor necrosis factor-α. 
 315 
Glycation markers were assessed for their capacity to discriminate between simple 316 
steatosis and NASH using ROC curves in the sub-sample of patients with biopsy and glycation 317 
measurement (n=22). In this small sample, CML, CEL, pentosidine and AGE fluorescence were 318 
considered as a non-valid instrument to discriminate between simple steatosis and NASH (AUC 319 
<0.60). Fructosamine, sRAGE, CML/sRAGE and CEL/sRAGE presented a “poor” ability to 320 
discriminate between simple steatosis and NASH (AUC=0.60-0.67). However, AGE 321 
fluorescence/sRAGE (AUC= 0.73) was considered to present a “fair” ability (AUC=0.73). Hence, 322 
no threshold values could be calculated for NASH and simple steatosis. To predict the likelihood 323 
of NASH vs simple steatosis, the ORs were calculated using glycation products/sRAGE levels as 324 
untransformed continuous variables (unadjusted and after adjustment for age and AST/ALT). 325 
None of the glycation biomarkers predicted the likelihood of having NASH, compared to simple 326 
steatosis (Supplement 9). Additionally, none of the markers or ratios did predict the likelihood 327 
of having fibrosis (defined as LSM>6.6kPa cut-off, Supplement 10). 328 
1.4 Discussion 329 
AGEs can exert pathological effects extracellularly, by inducing modifications of proteins, and 330 
intracellularly, by binding to the AGEs receptors (RAGE) [11]. The AGE/RAGE axis activates a 331 
positive feedback loop, which in turn lead to a cascade of events from chemotaxis, oxidative 332 
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stress and inflammation to cell dysfunction, fibrosis and apoptosis, ultimately manifesting as 333 
end-organ damage [13, 14]. Conversely, the decoy receptors sRAGE and esRAGE offer 334 
protection by preventing AGEs/RAGE interaction and removal of AGE-modified products [11]. 335 
Therefore, evaluating together glycation products with their decoy receptor sRAGE is an 336 
important strategy to better understand the development and progression of NAFLD.  337 
To the best of our knowledge, this is the first study to simultaneously explore the role of 338 
multiple glycation biomarkers (including early and advanced products) and their receptors 339 
(sRAGE) in NAFLD normo-glycemic patients as components of the multiple hits model of NAFLD, 340 
and the ratio of glycation products/sRAGE as a proxy for AGE/RAGE axis activation. An 341 
important finding was that the combination of AGEs with their scavenger receptor (sRAGE) as 342 
ratios made the associations between glycation markers and biochemical parameters of liver 343 
injury stronger than studying AGEs alone. Early and advanced glycation end-products (except 344 
CML) were 10-30% higher and CML/sRAGE, CEL/sRAGE and AGEs/sRAGE ratios 4-times higher in 345 
NAFLD cases compared to controls. However, ratios did not differ according to the presence of 346 
fibrosis or the stage of NAFLD (different levels of liver injury).  347 
CML is the most studied glycation product and is commonly used as a sole proxy for all 348 
AGEs. AGEs are formed under different pathways: CML is formed by the oxidative degradation 349 
of fructosamine, CEL can derive from a broad range of precursors (such as methylglyoxal), and 350 
pentosidine is derived from the glycation and oxidation of lysine and arginine. AGEs 351 
involvement in disease pathogenesis may also differ with CEL and CML acting through 352 
interaction with RAGE [37], while pentosidine and AGE fluorescence products acting through 353 
their cross-linking properties [37]. Our findings agree with the lack of difference observed 354 
between CML levels and hepatic impairment (with simple liver steatosis or NASH, and with 355 
NAFLD or normal liver function) in patients and age-, sex- and BMI-matched controls [38-41].  356 
The lower serum sRAGE levels in NAFLD cases compared to controls observed in this 357 
study are in agreement with previous reports. In cross-sectional studies of NAFLD cases, 358 
esRAGE [42] (57 NAFLD subjects vs 14 controls) and sRAGE [43] (60 cases with familial 359 
combined hyperlipidemia and/or metabolic syndrome vs 50 controls) levels were 40% lower in 360 
cases with NAFLD (esRAGE= 663pg/mL and sRAGE= 1065pg/mL), compared to control subjects 361 
(esRAGE= 897 pg/mL and sRAGE= 1480pg/mL). Similar to our findings, sRAGE levels were not 362 
different between the stages of NAFLD. In obese prepuberal children [44] (n=140, aged 6-10y), 363 
lower esRAGE and sRAGE were observed in individuals with liver steatosis compared to healthy 364 
controls (esRAGE, 790 vs 1500pg/ml; sRAGE, 1000 vs. 1350pg/mL).  365 
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Accurate noninvasive diagnosis for NAFLD (and stages) is of great relevance to identified 366 
patients at higher risk of liver-related morbidity and mortality [45]. AGEs/sRAGE ratios give an 367 
indication of the relative proportion of AGEs not binded to the decoy receptors and hence 368 
available to stimulate the intracellular events by AGE/RAGE axis activation. For instance, sRAGE 369 
(and esRAGE) are reported to be reduced in certain diseases (such as coronary artery disease) 370 
and elevated in others (such as diabetes and renal impairment) [22]. Similarly, CML levels are 371 
lower as BMI, waist circumference and body fat mass increase [38-41]. In this study, 372 
CML/sRAGE, CEL/sRAGE and AGEs/sRAGE ratios were used as proxies of the free glycation 373 
fraction able to elicit further molecular events. We observed higher ratios among cases 374 
compared to controls, without detectable differences between simple liver steatosis and NASH. 375 
Higher ratios of glycated products/sRAGE were associated with increased liver injury (lower 376 
AST/ALT ratios) in the ordinal regression models, even after adjustment for age, abdominal fat 377 
and inflammation. AGEs/sRAGE and CEL/sRAGE ratio presented a good ability to discriminate 378 
NAFLD from a normal liver function, as shown by ROC curves (AUC=0.85). Considering that 379 
AGEs quantification by HPLC-MS is not always possible, and adipose tissue may be a preferred 380 
tissue to measure CML as opposed to plasma, a simple fluorescence analysis to serum and a 381 
sRAGE measurement via ELISA presented similar capacity to detect liver damage and 382 
inflammation to their more sophisticated AGEs/sRAGE ratio. In fact, AGE fluorescence/sRAGE 383 
ratio analysis presented an AUC similar to CEL/sRAGE and AGEs/sRAGE. Due to its metabolic 384 
pathway AGE fluorescence could also indicate levels of cross-linked products formation which 385 
are more likely to represent liver damage and inflammation. Glycation products other than CML 386 
should be considered since obesity synergistically with metabolic syndrome are associated with 387 
7-10 fold increased risk of hepatic steatosis and fibrosis [46, 47]. However, AGE fluorescence is 388 
a non-specific method where any fluorescent adduct could be interfering in the analysis. Also, 389 
sRAGE levels should be interpreted accordingly with the physiological conditions (i.e. glycemic 390 
levels and renal function). 391 
Although histological samples are not always available, analysis of AGE and sRAGE with 392 
biopsies remain of interest. In vitro and animal models have shown that as AGEs accumulates in 393 
the liver, inflammation occurs followed by macro- and micro- vesicular steatosis. However, 394 
when AGE/RAGE interaction is blocked, the pro-inflammatory environment is suppressed [48-395 
50]. This highlights the relevance of AGEs/RAGE interaction in NAFLD progression. From the 22 396 
biopsies that were available from the NAFLD cases in this study, AGEs/sRAGE, CEL/sRAGE, 397 
sRAGE and AGE fluorescence/sRAGE were not associated with the likelihood of having simple 398 
liver steatosis or NASH. However, the small number of biopsies limited our study to fully 399 
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explore the relationship between glycation products and the presence of NASH. Limited 400 
number of studies, with 8 to 74 participants, have evaluated serum CML and sRAGE levels 401 
according to stages of NAFLD, with no differences observed between simple steatosis, 402 
borderline NASH and define NASH [38, 43, 50]. However, 30-50% higher CML levels in the liver 403 
have been observed in obese subjects (n=74) with moderate-severe steatosis and lobular 404 
inflammation (stage 1-3) compared to those with low grade of steatosis and no inflammation 405 
(stage 0) [50]. So far, there is no validated non-invasive biomarkers or predictive model to 406 
detect or distinguish NASH [51]. The marker of apoptosis, m30, is considered as promising non-407 
invasive biomarkers to predict the presence of NASH (sensitivity of 60-91% and specificity of 77-408 
96%). However the cut-off levels of m30 vary between studies (121-380 U/L) [52]. Different 409 
predictive models of NASH have been developed such as the HAIR score [53] and NASH test 410 
[54]. However, validation is needed for both non-invasive biomarkers and predicted models for 411 
clinical practices. 412 
In the present study, we also evaluated the association between AGEs/sRAGE and 413 
downstream RAGE inflammatory regulation (possibly via reduction of intracellular activation) 414 
[55]. Notable aspects include the absence of association between CML and any of the markers 415 
considered, the weak to inexistent relationships between inflammation markers IL-6 and hs-416 
CRP with the glycation markers studied (possibly due to the exogenous origin of CML and/or 417 
deposition in the adipose tissue, reducing our ability to detect an effect). Stronger associations 418 
were seen between sRAGE and the liver function/injury markers, which was also reflected in 419 
the association between ratios and the liver function/injury markers. These associations are 420 
relevant since ALT, HOMA-IR and the AST/ALT ratio are the first signs of the presence of NAFLD. 421 
However, several correlations between glycation products and liver markers were not 422 
maintained when cases and controls were analyzed independently, while some new association 423 
appeared significant in one of the subgroup only. This could be a product of the variability in 424 
data in each subset (case or control) and the smaller sample sizes when subsets are considered, 425 
this is especially true considering the narrower range of values for liver enzymes and glycation 426 
products in the controls. The inverse association of sRAGE with ALT, γGT and HOMA-IR was in 427 
accordance with Yilmaz et al. [43], Santilli et al. [42, 56] and D’adamo et al. [44] in patients with 428 
hyperlipidemia with or without NAFLD. Conversely, positive associations have been previously 429 
reported between liver function and sRAGE in diabetic patients [57]. To our advantage, only 430 
normo-glycemic subjects were included in the study, eliminating this confounding factor from 431 
the analysis. These findings strengthen the involvement of AGEs-RAGE axis in the pathogenesis 432 
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of NAFLD, whereas no associations were evident for markers of apoptosis, liver stiffness or 433 
NAFLD score. 434 
The current study has limitations that should be mentioned. Given the cross-sectional design of 435 
our study, no causal relations can be established. This matched case-control study sample size 436 
is similar to others in the field, but remains small when considering the staging of NAFLD – this 437 
might have limited our results to fully explore the relationship between glycation products and 438 
disease stages, and the correlations between glycation products and liver/inflammation 439 
biomarkers, according to the disease stage, especially when cases and controls were considered 440 
separately. As this was a single-centre study, results and glycation levels should be extrapolated 441 
to other population carefully. On the other hand, one strength of the study is the wide type of 442 
early and advanced glycation end-products included, analyzed using an accurate and precise 443 
method by ultra-high resolution LC-MS, to explore associations with NAFLD characteristics. 444 
Similarly, the serum levels of sRAGE included both sRAGE and esRAGE in the same ELISA kit. The 445 
inclusion of normo-glycaemic subjects only is an additional strength, excluding the effect of 446 
hyperglycemia on AGEs formation and sRAGE levels. 447 
In conclusion, these findings support the hypothesis that AGE/RAGE activation is 448 
involved in the development of liver injury as part of the multiple hit model and add 449 
information regarding the pathophysiology of the disease. The measurement of an AGEs/sRAGE 450 
ratio shows better capacity to detect end organ damage and downstream organ function (liver 451 
in our case) and is hence to be preferred versus studying AGEs or sRAGE levels in isolation. 452 
Evaluating AGEs/sRAGE ratio provides a new translational and clinical perspective to determine 453 
disease progression (related to NAFLD pathogenesis). Although glycation products/sRAGE ratios 454 
discriminated between healthy and NAFLD patients, reference values would need to be 455 
established and validated in different NAFLD populations. Given that our sample of patients 456 
with available biopsies was small, future studies may focus on whether the evaluation of 457 
protein glycation/sRAGE could discriminate between the stages of NAFLD and to evaluate their 458 
usefulness as a non-invasive way of staging NAFLD. Moreover, potential modulation of 459 
AGEs/RAGE axis through diet could be the aim of future studies. 460 
461 
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 615 
1.6 Supplements 616 
Tables 617 
Supplement 1. Liver, biochemical and inflammatory markers in NAFLD patients and their matched 618 
healthy controls 619 
 Cases (n= 58) Controls (n=58) p-value 
ALT (IU/L) 76.3 (41.3) 15.0 (5.9) <0.001 
AST (IU/L) 42.1 (19.1) 24.7 (6.8) <0.001 
γGT (IU/L) 98.7 (124.5) 20.2 (12.1) <0.001 
IL-6 (pg/mL) 2.3 (3.9)* 3.7 (9.3) 0.191 
IL-8 (pg/mL) 32.5 (51.4)* 33.8 (84.8) 0.089 
TNF-α (pg/mL) 4.8 (3.7) 2.5 (3.6) <0.001 
hsCRP (mg/L) 1.8 (2.0)* 1.2 (1.1) 0.027 
Adiponectin (mg/mL) 6.6 (4.7) 10.0 (7.7) 0.007 
VEGF (pg/mL) 317.7 (161.4)* 383.9 (231.9) 0.150 
TGF-β1 (mg/mL) 36.3 (12.9) 25.3 (14.4) 0.001 
Differences between cases and their matched controls (match by age, sex and BMI) were observed using 
Mann-Whitney U test. ALT, alanine aminotransferase; AST, Aspartate aminotransferase; γGT, γ-glutamyl 
transpeptidase; hsCRP, high sensitive C reactive protein; IL-6, interleukin 6; IL-8, interleukin 8; TGF-β1; 
transforming growth factor beta-1; TNF-α, tumor necrosis factor-α, VEGF; vascular endothelial factor. 
 620 
Supplement 2. Sensitive analysis of glycation biomarkers levels among the non-alcoholic fatty 621 
liver disease (NAFLD) patients with available biopsy (n=22) and healthy controls (n=22). 622 
 Cases (n=22) Controls (n=22) p-value 
Fructosamine (mM DMF) 1.2 (0.2) 1.0 (0.2) 0.009 
AGE fluo (AU)a 501.7 (438.3 – 584.8) 404.8 (377.9 – 429.9) 0.001 
AGEs (mmol/mol) 131.6 (34.0) 112.2 (25.6) 0.038 
CML mmol/mol 10.9 (4.3) 9.3 (2.3) 0.133 
CEL mmol/mol 119.0 (34.2) 101.4 (26.5) 0.06 
Pentosidine mmol/mola 1.6 (1.5 – 1.9) 1.6 (1.4 – 1.6) 0.07 
sRAGE (pg/L)a 322.8 (186.9 – 438.8) 602.7 (519.7 – 764.8) 0.001 
CML/sRAGE (mmol/pmol) a 1.2 (0.7 – 1.5) 0.5 (0.4 – 0.8) 0.001 
CEL/sRAGE (mmol/pmol) 19.6 (18.7) 6.3 (2.6) 0.002 
AGEs/sRAGE (mmol/pmol) 22.4 (22.9) 7.0 (2.8) 0.004 
Data are presented as means (SD) or a median (interquartile range). Differences between cases and 
their matched controls (match by age, sex and BMI) were observed using 2-samples t test or Mann-
Whitney U Test. AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-
carboxymethyl-L-lysine) and pentosidine. sRAGE, AGEs soluble receptor. 
 623 
 624 
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 625 
Supplement 3. Glycation biomarkers levels according to the necro-inflammatory grade score among patients with available biopsies (n=22). 626 
 Grade 0 (n=10) Grade 1 (n=4) Grade 2 (n=7) Grade 3 (n=1) p-value 
Fructosamine (mM DMF) 1.20 (0.99-1.39) 1.16 (1.03-1.45) 0.97 (0.93-1.23) 1.34 0.226 
AGE fluo (AU) 501.16 (474.97-549.97) 558.15 (438.28-634.17) 542.72 (414.55-586.84) 613.87 0.711 
AGEs (mmol/mol) 133.36 (99.78-167.11) 136.44 (121.64-142.64) 137.25 (103.84-138.34) 124.56 0.987 
CML mmol/mol 10.72 (5.73-13.22) 13.39 (12.17-14.93) 8.65 (6.62-11.03) 15.34 0.166 
CEL mmol/mol 121.50 (93.08-148.41) 120.58 (106.17-127.13) 124.64 (94.71-130.14) 107.02 0.902 
Pentosidine mmol/mol 1.65 (1.50-1.92) 1.85 (1.70-2.17) 1.56 (1.45-1.58) 2.19 0.139 
sRAGE (pg/L) 327.22 (285.20-388.62) 419.65 (310.56-927.74) 186.85 (157.10-442.09) 474.72 0.529 
CML/sRAGE (mmol/pmol) 1.06 (0.56-1.41) 1.29 (0.84-5.60) 1.17 (0.95-2.07) 1.13 0.773 
CEL/sRAGE (mmol/pmol) 13.06 (8.91-19.58) 10.65 (6.36-45.33) 22.35 (10.47-28.99) 7.89 0.533 
AGEs/sRAGE (mmol/pmol) 14.59 (10.02-21.42) 12.12 (7.30-51.83) 23.62 (11.58-30.82) 9.18 0.533 
Data are presented as median (interquartile range). Differences according to the grade of necro-inflammation (Brunt [29]) were performed among the groups with 
at least two patients, using Kruskal-Wallis Test. AGEs (advance glycation end products) is the sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-
lysine) and pentosidine. sRAGE, AGEs soluble receptor. 
 627 
Supplement 4. Glycation biomarkers levels according to fibrosis stage among patients with available biopsies (n=22). 628 
 Grade 0 (n=9) Grade 1 (n=4) Grade 2 (n=5) Grade 3 (n=4) p-value 
Fructosamine (mM DMF) 1.10 (0.99-1.41) 1.31 (1.16-1.39) 1.05 (1.01-1.23) 0.95 (0.91-1.16) 0.332 
AGE fluo (AU) 496.66 (431.50-529.91) 549.29 (438.28-600.07) 542.72 (491.86-546.01) 589.77 (478.62-603.28) 0.742 
AGEs (mmol/mol) 118.16 (99.78-148.55) 147.57 (121.64-163.72) 138.06 (137.25-138.08) 121.19 (110.83-131.45) 0.240 
CML mmol/mol 10.62 (5.73-12.27) 13.38 (12.17-15.61) 11.03 (10.68-14.78) 7.64 (5.69-12.00) 0.790 
CEL mmol/mol 109.25 (93.08-133.75) 133.74 (106.49-147.49) 124.64 (120.25-125.55) 109.26 (100.47-120.82) 0.784 
Pentosidine mmol/mol 1.58 (1.57-1.78) 1.85 (1.67-1.92) 1.58 (1.46-1.82) 1.57 (1.41-1.89) 0.759 
sRAGE (pg/L) 328.01 (319.14) 419.65 (310.56-438.77) 186.85 (95.57-442.09) 244.24 (165.86-394.29) 0.624 
CML/sRAGE (mmol/pmol) 0.70 (0.51-1.16) 1.35 (1.27-1.50) 2.07 (1.17-3.91) 1.05 (0.96-1.30) 0.212 
CEL/sRAGE (mmol/pmol) 10.21 (5.19-18.06) 12.73 (9.76-16.60) 23.35 (14.60-45.98) 16.41 (9.18-25.67) 0.465 
AGEs/sRAGE (mmol/pmol) 10.94 (6.48-18.77) 14.26 (11.19-18.31) 25.71 (15.89-50.56) 17.60 (10.38-27.22) 0.465 
Data are presented as median (interquartile range). Differences according to stage of fibrosis (Brunt [29]) were performed using Kruskal-Wallis Test. AGEs (advance 
glycation end products) is the sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and pentosidine. sRAGE, AGEs soluble receptor. 
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Supplement 5. Glycation biomarkers levels according to the stage of NAFLD based on the Kleiner 630 
score among patients with available biopsies. 631 
 Simple steatosis (n=10) NASH (n=12) p-value 
Fructosamine (mM DMF) 1.21 (0.28) 1.10 (0.18) 0.25 
AGE fluo (AU)a 533.08 (124.93) 511.22 (88.15) 0.67 
AGEs (mmol/mol) 127.49 (40.68) 135.01 (28.61) 0.62 
CML mmol/mol 11.28 (4.82) 10.57 (3.91) 0.71 
CEL mmol/mol 114.55 (41.42) 122.70 (28.27) 0.59 
Pentosidine mmol/mola 1.67 (0.28) 1.74 (0.34) 0.67 
sRAGE (pg/L)a 524.98 (396.65) 323.32 (243.49) 0.17 
CML/sRAGE (mmol/pmol) 2.95 (6.44) 2.09 (2.60) 0.68 
CEL/sRAGE (mmol/pmol) 15.58 (16.35) 23.00 (20.57) 0.37 
AGEs/sRAGE (mmol/pmol) 18.80 (23.00) 25.44 (23.44) 0.51 
Differences between cases and their matched controls (match by age, sex and BMI) were observed using 2-
samples t test or Mann-Whitney U Test a Data are not normally distributed. AGEs (advance glycation end 
products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and pentosidine. sRAGE, AGEs 
soluble receptor; NASH, non-alcoholic steatohepatitis. 
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Supplement 6. Spearman (rho) correlations between glycated products and sRAGE, and liver function and inflammation biomarkers in the cases 633 
(n=58). 634 
 ALT AST AST/ALT γGT HOMA-IR TGF-β1 TNF-α IL-6 hsCRP 
AGEs (sum of) 0.09 0.08 -0.03 -0.07 0.04 -0.18 0.10 <0.01 -0.08 
CML -0.05 -0.01 0.09 -0.17 -0.15 -0.13 -0.06 -0.06 -0.09 
CEL 0.08 0.05 -0.03 0.09 0.05 -0.17 0.10 <0.01 -0.05 
Pentosidine 0.10 0.11 -0.06 -0.07 0.10 0.11 0.02 0.09 -0.06 
Fructosamine -0.02 -0.02 0.03 -0.22 -0.06 0.07 <0.01 -0.41* -0.22 
AGE fluorescence -0.14 -0.18 0.14 0.10 -0.08 0.09 0.05 0.11 0.05 
sRAGE -0.01 0.22 -0.06 -0.26 -0.15 -0.14 -0.24 -0.16 -0.12 
CML/sRAGE -0.03 -0.16 0.02 0.13 0.04 0.10 0.18 0.12 0.06 
CEL/sRAGE -0.06 -0.24 <0.01 0.15 0.13 0.06 0.28* 0.22 0.14 
AGEs/sRAGE -0.05 -0.24 -0.02 0.16 0.12 0.06 0.28* 0.21 0.13 
*p = 0.002. AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 
pentosidine. ALT, alanine aminotransferase; AST, aspartate aminotransferase; γGT, γ-glutamyl transpeptidase; HOMA-IR, (log) 
Homeostasis Model of Assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IL-6: interleukin 6; sRAGE, AGEs 
soluble receptor; TGF-β1, Transforming growth factor beta 1; TNF-α, Tumor necrosis factor-α. 
 635 
Supplement 7. Spearman (rho) correlations between glycated products and sRAGE, and liver function and inflammation biomarkers in the controls 636 
(n=58).  637 
 ALT AST AST/ALT γGT HOMA-IR TGF-β1 TNF-α IL-6 hsCRP 
AGEs (sum of) -0.45** -0.43** 0.16 -0.18 0.11 0.36** -0.38** -0.24 -0.05 
CML 0.16 0.26 0.03 0.18 0.07 -0.09 0.10 0.12 -0.26 
CEL -0.43** -0.45** 0.13 -0.18 0.10 0.36** -0.35* -0.26 -0.02 
Pentosidine -0.11 -0.08 0.10 -0.06 0.16 -0.16 0.20 0.10 0.02 
Fructosamine 0.13 0.14 -0.11 -0.13 0.18 0.07 -0.31* -0.21 -0.20 
AGE fluorescence 0.01 -0.07 0.01 0.03 0.03 -0.07 0.33** -0.20 -0.10 
sRAGE 0.10 0.19 -0.03 -0.10 0.05 0.05 0.05 0.16 0.26 
CML/sRAGE -0.08 -0.11 0.08 0.17 -0.05 -0.06 0.03 -0.08 0.13 
CEL/sRAGE -0.33* -0.39** 0.14 -0.03 0.05 0.17 -0.27 -0.23 0.12 
AGEs/sRAGE -0.32* -0.39** 0.13 -0.02 0.04 0.16 -0.26 -0.21 0.14 
*p = 0.02, ** p < 0.01; AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 
pentosidine. ALT, alanine aminotransferase; AST, aspartate aminotransferase; γGT, γ-glutamyl transpeptidase; HOMA-IR, (log) Homeostasis 
Model of Assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IL-6: interleukin 6; sRAGE, AGEs soluble receptor; TGF-
β1, Transforming growth factor beta 1; TNF-α, Tumor necrosis factor-α. 
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Supplement 8. Multinominal logistic regression analysis (OR, 95%CI), exploring the association between sRAGE and glycated products/sRAGE 639 
ratio with AST/ALT (N= 58 cases and 58 controls). 640 
 AST/ALT quartiles Model 1 a Model 2 b Model 3 c 
sRAGE     
 Q1 (<0.55) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 
 Q2 (0.55 – 0.95) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 
 Q3 (0.96 – 1.72) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 1.00 (0.99 – 1.00) 
AGEs/sRAGE     
 Q1 (<0.55) 1.27 (1.10 – 1.47)* 1.31 (1.10 – 1.57)* 1.35 (1.10 – 1.65)* 
 Q2 (0.55 – 0.95) 1.27 (1.10 – 1.47)* 1.31 (1.10 – 1.57)* 1.35 (1.10 – 1.64)* 
 Q3 (0.96 – 1.72) 1.02 (0.87 – 1.19) 1.08 (0.89 – 1.30) 1.13 (0.92 – 1.40) 
CML/sRAGE     
 Q1 (<0.55) 13.28 (2.35 – 75.20)* 26.64 (2.74 – 258.79)* 28.18 (2.80 – 283.72)* 
 Q2 (0.55 – 0.95) 14.27 (2.52 – 80.77)* 27.57 (2.84 – 267.99)* 29.00 (2.88 – 292.16)* 
 Q3 (0.96 – 1.72) 1.79 (0.27 – 12.08) 3.12 (0.28 – 34.97) 4.35 (0.36 – 52.94) 
CEL/sRAGE     
 Q1 (<0.55) 1.29 (1.10 – 1.50)* 1.33 (1.10 – 1.60)* 1.37 (1.11 – 1.69)* 
 Q2 (0.55 – 0.95) 1.29 (1.10 – 1.50)* 1.32 (1.10 – 1.60)* 1.36 (1.10 – 1.68)* 
 Q3 (0.96 – 1.72) 1.01 (0.86 – 1.20) 1.08 (0.88 – 1.31) 1.14 (0.91 – 1.42) 
AGE fluorescence/sRAGE     
 Q1 (<0.55) 1.32 (1.14 – 1.54)* 1.33 (1.12 – 1.58)* 1.35 (1.13 – 1.61)* 
 Q2 (0.55 – 0.95) 1.33 (1.15 – 1.55)* 1.34 (1.13 – 1.59)* 1.35 (1.13 – 1.61)* 
 Q3 (0.96 – 1.72) 1.08 (0.92 – 1.26) 1.09 (0.91 – 1.31) 1.12 (0.93 – 1.34) 
The reference value is an AST/ALT (aspartate aminotransferase/alanine aminotransferase) ratio higher than 1.72(Q4). *p < 0.01.  
a Model 1: univariate, unadjusted  
b Model 2: adjusted for age, gender, abdominal fat level. 
c Model 3: adjusted for age, gender, abdominal fat level, interleukin 6 and high-sensitive C-reactive protein. 
Advance glycation end products (AGEs) including Nε-carboxymethyl-L-lysine (CML), Nε-carboxyethyl-L-lysine (CEL) and pentosidine, and sRAGE 
(AGEs soluble receptor) are expressed as continuous variables. 
28 
 
Supplement 9. Logistic regression analysis models, exploring the association between glycated 641 
products/sRAGE ratio, sRAGE, and the likelihood of NASH (n=12) against simple steatosis (n=10). 642 
 Model 1a Model 2b 
 OR 95% CI P OR 95% CI P 
sRAGE  0.99 0.99-1.00 0.17 0.99 0.99-1.00 0.17 
AGEs/sRAGE  1.01 0.97-1.06 0.50 1.01 0.97-1.06 0.53 
CEL/sRAGE  1.03 0.97-1.08 0.37 1.02 0.97-1.08 0.40 
AGE fluorescence/sRAGE  1.12 0.97-1.30 0.11 1.15 0.97-1.35 0.10 
a Model 1: unadjusted. 
b Model 2: adjusted for age and AST/ALT. 
NAFLD: non-alcoholic fatty liver disease, OR: Odds Ratio, CI: Confidence Interval, CEL: Nε-carboxyethyl-L-
lysine, AGEs: Nε-carboxymethyl-L-lysine, CEL and pentosidine advance glycation end products, sRAGE: AGEs 
soluble receptor, HOMA-IR: Homeostasis Model of Assessment of insulin resistance, γGT: γ-glutamyl 
transpeptidase.  
 643 
 644 
Supplement 10. Logistic regression analysis models, exploring the association between glycated 645 
products/sRAGE ratio, sRAGE, and the likelihood of having fibrosis (defined as LSM>6.6 kPa cut-off). 646 
 Model 1a Model 2b 
 OR 95% CI P OR 95% CI P 
sRAGE  0.99 0.99-1.00 0.15 0.99 0.99-1.00 0.09 
AGEs/sRAGE  0.99 0.98-1.02 0.86 1.00 0.98-1.02 0.99 
CEL/sRAGE  1.00 0.98-1.02 0.96 1.00 0.98-1.03 0.90 
AGE fluorescence/sRAGE  0.99 0.97-1.01 0.48 0.99 0.99-1.02 0.57 
a Model 1: unadjusted. 
b Model 2: adjusted for age and AST/ALT. 
Twenty-seven NAFLD patients with a liver stiffness measurement (LSM) <6.6 kPa and 18 NAFLD patients 
with LSM > 6.6 kPa. NAFLD: non-alcoholic fatty liver disease, OR: Odds Ratio, CI: Confidence Interval, AGEs 
(advance glycation end products) includes: Nε-carboxymethyl-L-lysine, Nε-carboxyethyl-L-lysine (CEL) and 
pentosidine, sRAGE: AGEs soluble receptor, HOMA-IR: Homeostasis Model of Assessment of insulin 
resistance, γGT: γ-glutamyl transpeptidase.  
 647 
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Figures 648 
 649 
Supplementary figure 1. Correlation between glycated products and sRAGE (AGEs soluble receptor), and alanine aminotransferase (ALT) in cases (green 650 
triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 651 
pentosidine. 652 
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 653 
Supplementary figure 2. Correlation between glycated products and sRAGE (AGEs soluble receptor), and aspartate aminotransferase (AST) in cases (green 654 
triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 655 
pentosidine. 656 
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 657 
Supplementary figure 3. Correlation between glycated products and sRAGE (AGEs soluble receptor), and aspartate aminotransferase (AST)/ alanine 658 
aminotransferase (ALT) ratio in cases (green triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-659 
lysine), CML (Nε-carboxymethyl-L-lysine) and pentosidine. 660 
 661 
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 662 
Supplementary figure 4. Correlation between glycated products and sRAGE (AGEs soluble receptor), and γ-glutamyl transpeptidase (γGT) in cases (green 663 
triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 664 
pentosidine. 665 
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 666 
Supplementary figure 5. Correlation between glycated products and sRAGE (AGEs soluble receptor), and homeostasis Model of Assessment of insulin 667 
resistance (HOMA-IR, log) in cases (green triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-668 
lysine), CML (Nε-carboxymethyl-L-lysine) and pentosidine. 669 
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 670 
Supplementary figure 6. Correlation between glycated products and sRAGE (AGEs soluble receptor), and Transforming growth factor beta 1 (TGF-β1) in 671 
cases (green triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-672 
L-lysine) and pentosidine. 673 
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 674 
Supplementary figure 7. Correlation between glycated products and sRAGE (AGEs soluble receptor), and Tumor necrosis factor-α (TNF-α) in cases (green 675 
triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and 676 
pentosidine. 677 
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 678 
Supplementary figure 8. Correlation between glycated products and sRAGE (AGEs soluble receptor), and interleukin 6 (IL-6) in cases (green triangles) and 679 
controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-lysine) and pentosidine. 680 
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 681 
Supplementary figure 9. Correlation between glycated products and sRAGE (AGEs soluble receptor), high-sensitivity C-reactive protein (hsCRP) in cases 682 
(green triangles) and controls (blue circles). AGEs (advance glycation end products) sum of CEL (Nε-carboxyethyl-L-lysine), CML (Nε-carboxymethyl-L-683 
lysine) and pentosidine. 684 
